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Myotonic dystrophy types 1 and 2 are progressive multisystemic disorders with potential brain involvement. We compared 22
myotonic dystrophy type 1 and 22 myotonic dystrophy type 2 clinically and neuropsychologically well-characterized patients
and a corresponding healthy control group using structural brain magnetic resonance imaging at 3 T (T1/T2/diffusion-weighted).
Voxel-based morphometry and diffusion tensor imaging with tract-based spatial statistics were applied for voxel-wise analysis
of cerebral grey and white matter affection (Pcorrected50.05). We further examined the association of structural brain changes
with clinical and neuropsychological data. White matter lesions rated visually were more prevalent and severe in myotonic
dystrophy type 1 compared with controls, with frontal white matter most prominently affected in both disorders, and temporal
lesions restricted to myotonic dystrophy type 1. Voxel-based morphometry analyses demonstrated extensive white matter
involvement in all cerebral lobes, brainstem and corpus callosum in myotonic dystrophy types 1 and 2, while grey matter
decrease (cortical areas, thalamus, putamen) was restricted to myotonic dystrophy type 1. Accordingly, we found more prom-
inent white matter affection in myotonic dystrophy type 1 than myotonic dystrophy type 2 by diffusion tensor imaging.
Association ﬁbres throughout the whole brain, limbic system ﬁbre tracts, the callosal body and projection ﬁbres (e.g. intern-
al/external capsules) were affected in myotonic dystrophy types 1 and 2. Central motor pathways were exclusively impaired in
myotonic dystrophy type 1. We found mild executive and attentional deﬁcits in our patients when neuropsychological tests were
corrected for manual motor dysfunctioning. Regression analyses revealed associations of white matter affection with several
clinical parameters in both disease entities, but not with neuropsychological performance. We showed that depressed mood and
fatigue were more prominent in patients with myotonic dystrophy type 1 with less white matter affection (early disease stages),
contrary to patients with myotonic dystrophy type 2. Thus, depression in myotonic dystrophies might be a reactive adjustment
disorder rather than a direct consequence of structural brain damage. Associations of white matter affection with age/disease
duration as well as patterns of cerebral water diffusion parameters pointed towards an ongoing process of myelin destruction
doi:10.1093/brain/awr299 Brain 2011: 134; 3527–3543 | 3527
Received June 8, 2011. Revised August 7, 2011. Accepted September 16, 2011
 The Author (2011). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0),
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.and/or axonal loss in our cross-sectional study design. Our data suggest that both myotonic dystrophy types 1 and 2 are serious
white matter diseases with prominent callosal body and limbic system affection. White matter changes dominated the extent of
grey matter changes, which might argue against Wallerian degeneration as the major cause of white matter affection in myo-
tonic dystrophies.
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Abbreviations: BDI = Beck Depression Inventory; DTI = diffusion tensor imaging; KFSS = Krupp’s fatigue severity scale;
PSQI = Pittsburgh sleep quality index; VBM = voxel-based morphometry
Introduction
Myotonic dystrophy types 1 and 2 are autosomal dominantly in-
herited, progressive multisystemic disorders. Myotonic dystrophy
type 1 is the most common form of muscular dystrophy in
adults. Both types are caused by untranslated nucleotide repeat
expansions in two distinct genes leading to RNA pathology and
aberrant alternative splicing of several genes (Day and Ranum,
2005). While myotonic dystrophy type 1 results from a CTG
repeat expansion in the dystrophia myotonica-protein kinase
gene (DMPK), a CCTG repeat expansion in the zinc ﬁnger protein
9 gene (ZNF9) has been identiﬁed in myotonic dystrophy type 2
(Brook et al., 1992; Liquori et al., 2001). In myotonic dystrophy
type 1, the classic disease range of CTG repeat numbers is
50–4000, in which repeat sizes of 50–80 may be associated
with mild clinical phenotypes, and large repeat expansions up to
4000 are often found in severe, mostly congenital forms of the
disorder.
There is ample evidence of cerebral involvement in myotonic
dystrophy type 1 and 2, albeit less severe in type 2
(Machuca-Tzili et al., 2005; Meola and Sansone, 2007). Mental
impairment, executive dysfunctioning and avoidant personality
traits—eventually deteriorating with age—have been described in
myotonic dystrophy types 1 and 2 (Meola et al., 2003; Gaul et al.,
2006; Modoni et al., 2008; Weber et al., 2010). Sleepiness and
fatigue constitute major complaints in myotonic dystrophy type 1
and type 2 (Giubilei et al., 1999; Laberge et al., 2009a, b;
Tieleman et al., 2010). The pathogenesis of CNS symptoms is
not entirely clear. Neuroﬁbrillary degeneration with intraneuronal
accumulation of abnormally modiﬁed microtubuli-associated tau
protein has been demonstrated in the brains of patients with myo-
tonic dystrophy types 1 and 2 (Sergeant et al., 2001; Maurage
et al., 2005; Itoh et al., 2010). Aberrant tau expression by dysre-
gulated alternative splicing has been proven in myotonic dystro-
phies allocating these disorders to a subset of neurodegenerative
diseases termed tauopathies (Jiang et al., 2004; Day and Ranum,
2005; Maurage et al., 2005; Leroy et al., 2006; Dhaenens et al.,
2008; Ghanem et al., 2009).
Brain involvement in myotonic dystrophy types 1 and 2 has
been demonstrated in vivo using different neuroimaging tech-
niques. MRI studies revealed white matter lesions and diffuse
brain atrophy in myotonic dystrophy types 1 and 2. White
matter lesions located within anterior temporal lobes represent
a characteristic feature in myotonic dystrophy type 1 (Hund
et al., 1997; Kassubek et al., 2003; Kornblum et al., 2004;
Romeo et al., 2010). Cellular markers in magnetic resonance spec-
troscopy were reduced in occipital and temporoparietal cortical
regions as well as frontal white matter of patients with myotonic
dystrophy types 1 and 2 (Vielhaber et al., 2006). Single photon
emission CT and PET studies demonstrated hypoperfusion and
glucose hypometabolism of frontal and temporal lobes in myotonic
dystrophy type 1, more so than in type 2 (Meola et al., 1999;
Weber et al., 2010).
In myotonic dystrophy type 1, grey matter reductions have been
described in various cortical regions and recently also in hippo-
campi and thalami using voxel-based morphometry (VBM)
(Antonini et al., 2004; Weber et al., 2010). T2 relaxometry, dif-
fusion MRI studies applying diffusion tensor imaging (DTI), and
magnetization transfer imaging showed white matter changes in
myotonic dystrophy type 1 using region of interest-based
approaches (Di Costanzo et al., 2001; Naka et al., 2002;
Fukuda et al., 2005). Atrophy or hypoplasia of the corpus callo-
sum had been described mainly in the congenital disease form of
myotonic dystrophy type 1, but a recent diffusion MRI study
applying DTI showed widespread white matter abnormalities in
congenital, as well as patients with juvenile-onset myotonic dys-
trophy type 1 (Hashimoto et al., 1995; Wozniak et al., 2011).
Giubilei et al. (1999) reported corpus callosum atrophy in a
small group of adult patients with myotonic dystrophy type 1.
Analysing the regional structural changes of the corpus callosum
by the diffusion tensor in DTI, a previous diffusion MRI study
found associations with volume loss in corresponding cortical re-
gions. Thus, Wallerian degeneration was postulated as a major
cause of white matter affection in myotonic dystrophy type 1
(Ota et al., 2006).
In patients with myotonic dystrophy type 2, we recently demon-
strated callosal body affection applying VBM, while grey matter
reduction was present in hypothalamic, thalamic and brainstem
regions (Minnerop et al., 2008). Weber et al. (2010) found
reduced grey matter volumes in their myotonic dystrophy type 2
sample in several cortical regions, including hippocampi and
thalami.
While some studies showed correlations of brain morphological
changes with neuropsychological and clinical parameters including
CTG repeat sizes in myotonic dystrophy type 1 (Ota et al., 2006;
Kuo et al., 2008; Romeo et al., 2010; Weber et al., 2010;
Wozniak et al., 2011), others failed to do so (Kassubek et al.,
2003; Antonini et al., 2004; Fukuda et al., 2005; Di Costanzo
et al., 2008).
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necting white matter is a potential mechanism for cognitive dys-
function in various neurological disorders (Dineen et al., 2009),
and may also be responsible for CNS symptoms in myotonic dys-
trophies. Imaging techniques differ regarding their ability to inves-
tigate white matter alterations. VBM allows a voxel-wise analysis
independent of predeﬁned regions of interests, but it is based on
signal differences of grey and white matter in T1-weighted MRIs
with a methodological-based focus for grey matter. Contrary, DTI
is a quantitative technique that measures tissue properties, i.e.
diffusivity and the directional dependence of microscopic diffusion
of water molecules in the brain especially in white matter (Catani,
2006). In white matter, diffusion is usually hindered by the high
degree of structural organization, resulting in anisotropic move-
ment of water molecules predominantly parallel to the orientation
of ﬁbre tracts. A lower fractional anisotropy signiﬁes less aniso-
tropic diffusion and thus lower microstructural integrity (Basser
and Jones, 2002). While previous diffusion MRI studies allowed
only a region of interest-based analysis of fractional anisotropy
values, the new technique ‘tract-based spatial statistics’ enables
a voxel-wise analysis of the microstructural integrity of white
matter across subjects (Smith et al., 2006).
For a comprehensive analysis of brain structure alterations in
myotonic dystrophies, we examined the brains of 22 myotonic
dystrophy type 1 and 22 myotonic dystrophy type 2 clinically
and neuropsychologically well-characterized patients and a corres-
ponding healthy control group with structural MRI. White matter
lesions were rated visually on T2-weighted images, and
voxel-based analyses of T1-weighted and diffusion-weighted
images (VBM and DTI/tract-based spatial statistics) were applied.
We hypothesized that white matter abnormalities and callosal
body affection are present in adult patients with both myotonic
dystrophy types 1 and 2 and are more frequent and pronounced
as previously suggested. We further aimed to analyse if abnormal
white matter integrity was associated with distinct clinical param-
eters and neuropsychological performance; and whether brain
morphological changes play a direct causative role in the develop-
ment of mood disturbances and increased daytime sleepiness or
fatigue. Finally, we intended to evaluate the inﬂuence of age and
disease duration on brain structural damage to further examine
the hypothesis of premature ageing in myotonic dystrophies.
Materials and methods
Subjects
All analyses were performed in 22 patients with myotonic dystrophy
type 1 (male/female: 9/13, age 43.1  12.6years, disease duration
13.2  7.0years) and 22 patients with myotonic dystrophy type 2
(male/female: 12/10, age 52.5  10.1years, disease duration
11.9  9.9years) as well as age- and sex-matched healthy controls
(male/female: 11/11, age 50.0  10.2years). Congenital or
infantile-onset forms of myotonic dystrophy type 1 were excluded
from this study. Diagnoses were conﬁrmed by genetic testing in all
cases. CTG repeat expansion sizes were determined in all patients with
myotonic dystrophy type 1 (mean  SD 614  306, range 80–1100
repeats). None of the patients and control subjects had a past medical
history of other neuromuscular or CNS disorders. All subjects under-
went clinical–neurological examinations and neuropsychological test-
ing. Education was assessed as a combination score of graduation
and professional qualiﬁcation (sum score), in which score points
were given for each school year (up to 13 in Germany), and 3–5
points for the professional qualiﬁcation (professional education and/
or study). In myotonic dystrophy type 1, the Muscular Impairment
Rating Scale was used to assess disease severity (Mathieu et al.,
2001). Evaluated scales for the assessment of disease severity or mus-
cular symptoms are not yet available in myotonic dystrophy type 2.
Characteristics of patients and controls are given in Table 1.
The local ethics committee approved the study protocol. Informed
written consent was obtained from all participants.
Neuropsychological testing
Cognitive functioning was assessed in patients and controls using a
comprehensive neuropsychological test battery. We applied several
questionnaires to assess increased daytime sleepiness and fatigue as
well as depression. Since motor function affected the majority of
neuropsychological test performances, we included the bimanual task
of the ‘Pegboard Puzzle’ (Tifﬁn, 1987; lower values corresponding to a
worse test result) as covariate to correct for motor impairment in test
performance. MRI correlation analyses were restricted to those clinical
and neuropsychological parameters with a signiﬁcant difference com-
pared with controls.
A detailed description of the test battery together with extensive
information on statistical analyses of clinical and neuropsychological
data is provided in the Supplementary material.
Table 1 Clinical characteristics of patients with myotonic dystrophy type 1 and myotonic dystrophy type 2 and healthy
controls (mean  SD)
Myotonic dystrophy
type 1 patient group
Myotonic dystrophy
type 2 patient group
Control
group
n 22 22 22
Age 43.1  12.6* 52.5  10.1 50.1  9.0
Sex (M/F) 9/13 12/10 11/11
CTG repeat length (range) 614  306 (80–1100) – –
Educational level 10.3  2.6* 11.6  2.1 11.7  1.8
Duration of disease (years) 13.2  7.0 11.9  9.9 –
Severity of disease (Muscular Impairment Rating Scale) 3.6  0.9 – –
Motor performance (Purdue Pegboard bimanual, cut-off511 pairs in 30s) 9.5  2.5* 10.3  1.9* 11.6  1.3
Depressed mood (BDI score, cut off410) 9.3  7.8* 8.7  7.2* 2.1  3.5
Educational levels were assessed as a combination score of graduation and professional qualiﬁcation (sum score).
*P50.05, i.e. signiﬁcant difference compared with control group.
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We acquired all MRI data at the Life & Brain Centre Bonn, Germany,
using a 3T scanner (Magnetom Trio, Siemens). An eight-channel head
coil was used for signal reception. All subjects underwent the same
imaging protocol consisting of whole brain T1-weighted, T2-weighted
and diffusion-weighted imaging using an in-house DTI sequence. The
total study time was 40min per subject, and all images were ob-
tained in one session. Further details of MRI data acquisition are given
in the Supplementary material. Image quality was controlled by visual
inspection, and images with artefacts were excluded from further data
analysis.
Grading of white matter
hyperintensities
White matter lesions (55mm) were quantiﬁed on T2-images accord-
ing to the age-related white matter change score (ARWMC; Wahlund
et al., 2001), which was used in myotonic dystrophy types 1 and 2
recently (Romeo et al., 2010). The grading within ﬁve regions, separ-
ately for each hemisphere, ranged from 0 (no lesions) to 3 (diffuse
involvement of the entire region).
Voxel-based morphometry
Image processing and statistical analyses were carried out according to
the optimized VBM protocol (Ashburner and Friston, 2000; Good
et al., 2001) using MATLAB 7.4.0 and statistical parametric mapping
(SPM 5; http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm5). Further
details of VBM analysis are described in the Supplementary material.
Using the smoothed tissue segments, we performed two-sample
t-tests comparing each patient group with controls, separately for
grey and white matter. The results were explored at a false discovery
rate-corrected threshold of P50.05 at voxel-level with an extended
cluster threshold of 10 voxels.
Diffusion tensor imaging
Preprocessing and analysis of diffusion data were done with an
in-house protocol using FMRIB software library (FSL) 4.1.3 tools (avail-
able at www.fmrib.ox.ac.uk/fsl). A diffusion tensor was reconstructed,
and the following indices were generated using DTIﬁt (Smith et al.,
2004): fractional anisotropy, mean diffusivity, eigenvalues (1, 2, 3)
of the diffusion tensor with axial diffusivity (1) presumed to be the
diffusivity parallel/along the axon, and radial diffusivity [(2 + 3)/2]
presumed to be the diffusivity perpendicular to the axon. For voxel-
wise analysis of the resulting maps, we used the tract-based spatial
statistics (version 1.1) tool also included in FSL (Smith et al., 2006).
Statistical analysis included (i) group comparisons using two-sample
t-tests between myotonic dystrophy type 1/myotonic dystrophy type
2 groups and healthy controls with respect to fractional anisotropy,
mean diffusivity, axial and radial diffusivity (PFWE50.05) and (ii) cor-
relation analyses (only for fractional anisotropy maps) in both patient
groups, using simple regression models with clinical parameters as
determining regressors (Pthreshold-free cluster enhancement50.05). Further
details of DTI data analysis are given in the Supplementary material.
Results
Clinical characteristics of myotonic
dystrophy types 1 and 2
Patients with myotonic dystrophy type 1 were younger than con-
trols (P = 0.04), had poorer motor performance (lower values indi-
cating worse performance in the bimanual pegboard task,
P = 0.001), fewer years of education (P = 0.049) and higher
Beck Depression Inventory (BDI) scores (Hautzinger et al., 1995)
indicating more depressive symptoms (P = 0.001), although the
group mean score value was still below the clinical cut-off (BDI
score 9.3  7.8). BDI scores above the clinical cut-off were found
in 7/22 patients with myotonic dystrophy type 1 (32%).
Patientswithmyotonicdystrophytype2didnotdifferfromcontrols
with respect to age and education, but showed poorer motor per-
formance (P = 0.011) and higher BDI scores (P = 0.001). Although
the group mean score value was still below the clinical cut-off (BDI
score 8.7  7.2), clinically relevantly elevated BDI scores were found
in 8/22 patients with myotonic dystrophy type 2 (38%).
Patients with myotonic dystrophy types 1 and 2 did not differ
from controls regarding sex distribution. Further, in both patient
groups age did not correlate with disease duration, and BDI scores
were not associated with age, disease duration or motor perform-
ance. In patients with myotonic dystrophy type 1, CTG repeat
lengths did not correlate with age, disease duration, muscular im-
pairment rating scale, motor performance or BDI scores.
Comparing patient groups, patients with myotonic dystrophy
type 1 were younger than patients with myotonic dystrophy type
2( P = 0.010), but did not differ with regard to depressed mood,
education, motor performance and disease duration (Table 1).
Neuropsychological performance
Neuropsychological performance – group comparison –
myotonic dystrophy type 1 and controls
Patients with myotonic dystrophy type 1 had a higher susceptibil-
ity to interference compared with our control group. However, the
test value was still within the normal range, when compared with
the clinical cut-off value for relevant impairment (P = 0.380;
Table 2). In contrast, patients with myotonic dystrophy type 1
performed better than controls in the choice reaction time and
the recognition task of the verbal memory test. Our control
group showed poorer performance in the choice reaction time
task in comparison to normative data (P = 0.036). Thus, choice
reaction time task results in patients with myotonic dystrophy
type 1 did not differ from normative data (P = 0.807). Patients
with myotonic dystrophy type 1 performed better in the verbal
memory task not only when compared with our control group but
also when compared with normative values (P = 0.033; Table 2).
Analysis of increased daytime sleepiness/fatigue showed that
our myotonic dystrophy type 1 patient group reached higher
scores than controls in all applied scales. However, mean scores
above the clinical cut-off of pathological performing were found in
15/22 (68%) patients with myotonic dystrophy type 1 with
Krupp’s Fatigue Severity Scale (KFSS; Krupp et al., 1989), in
3530 | Brain 2011: 134; 3527–3543 M. Minnerop et al.12/22 (55%) patients with myotonic dystrophy type 1 with
Daytime Sleepiness Scale (Johnson et al., 1999) and in 9/22
(41%) patients with myotonic dystrophy type 1 with Pittsburgh
Sleep Quality Index (PSQI; Buysse et al., 1989; Table 3).
We did not ﬁnd any correlations between neuropsychological
test results, sleepiness/fatigue scores and CTG repeat expansion
sizes. Correlation analyses, however, showed that worse results in
interference and choice reaction tasks were associated with higher
age and poorer motor performance, whereas the verbal memory
task correlated with age only. Higher KFSS, Daytime Sleepiness
Scale and PSQI scores were associated with more depressed
mood, but not with higher age or longer disease duration. Only
higher KFSS scores indicating more fatigue were associated with
poorer motor performance (Table 4).
Neuropsychological performance – group comparison –
myotonic dystrophy type 2 and controls
Patients with myotonic dystrophy type 2 showed poorer perform-
ance in focused attention and interference tasks compared with
controls (Table 2). Myotonic dystrophy type 2 differed from con-
trols in KFSS and PSQI scores with mean values scoring above the
clinical cut-off: 14/21 (70%) and 9/21 (43%) patients with myo-
tonic dystrophy type 2 reached pathological values, respectively.
Daytime Sleepiness Scale and Epworth Sleepiness Scale scores
(Johns, 1991) did not differ between patients with myotonic dys-
trophy type 2 and controls (Table 3).
In patients with myotonic dystrophy type 2, poorer performance
in an interference task was associated with poorer motor perform-
ance, whereas no associations with age or disease duration were
found. While Daytime Sleepiness Scale and PSQI scores showed
no correlations at all, higher KFSS scores were associated with
poorer motor performance, but not with higher age, longer dis-
ease duration or higher BDI scores (Table 4).
Neuropsychological performance – group comparison –
myotonic dystrophy types 1 and 2
Patients with myotonic dystrophy type 2 performed better than
patients with myotonic dystrophy type 1 in visual–spatial and vis-
ual–constructive abilities when corrected for motor performance.
Patients with myotonic dystrophy type 1 performed better
than patients with myotonic dystrophy type 2 in tests for choice
reaction time, interference and verbal memory (Table 2). Myotonic
dystrophy type 1 had higher Ullanlinna scores (Ullanlinna-
Narcolepsy Scale; Hublin et al., 1994) indicating more signs of
narcolepsy than myotonic dystrophy type 2; however, mean
score values were below the clinical cut-off in both groups
(Table 3). All other neuropsychological parameters did not differ
between patients with myotonic dystrophy types 1 and 2.
Grading of white matter
hyperintensities
Patients with myotonic dystrophy type 1 had more frequent and
severe white matter lesions than controls in total white matter
lesions scores assessing the whole brain (sum of bihemispheric
scores/total score, P = 0.03). Frontal brain regions were the most
frequently and severely affected areas in patients with myotonic
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The brain in myotonic dystrophies Brain 2011: 134; 3527–3543 | 3531dystrophy types 1 and 2 compared with controls (sum of bihemi-
spheric subscores, myotonic dystrophy type 1 P50.001, myotonic
dystrophy type 2 P = 0.02). Temporal white matter lesions were
restricted to patients with myotonic dystrophy type 1. Mild infra-
tentorial white matter lesions (subscore 1) were only found in one
control, mild parieto-occipital and unilateral frontal lesions were
present in three and two controls, respectively (subscores 1).
The remaining controls did not show white matter lesions
(Table 5). Both patient groups did not differ with regard to total
white matter lesions scores or subscores.
Voxel-based morphometry
Compared with controls, we found grey matter alterations in pa-
tients with myotonic dystrophy type 1 in various cortical regions of
both hemispheres, mainly located in frontal and parietal regions,
whereas temporal lobes were spared. Most notably, pre- and
postcentral gyrus and the supplementary motor area were bilat-
erally affected. Additional subcortical grey matter alteration was
detected in the right posterior thalamus and in the most anterior
part of the right putamen.
White matter decrease was more pronounced than grey matter
decrease. It affected the entire corpus callosum, both fornices,
cingulum bundle and white matter in every lobe. Further white
matter decrease was located at brainstem level (pons), along
middle cerebellar peduncles and in cerebellar white matter
(Supplementary Table 1; Fig. 1).
In contrast to myotonic dystrophy type 1, no grey matter de-
crease was detected in patients with myotonic dystrophy type 2
compared with controls. White matter decrease, however, was
pronounced and located along the entire corpus callosum and in
every lobe, although the regions were less conﬂuent than in myo-
tonic dystrophy type 1. Further, white matter loss was present at
brainstem level (pons), along middle cerebellar peduncles and in
cerebellar white matter (Supplementary Table 2; Fig. 1).
Diffusion tensor imaging
Diffusion tensor imaging – group comparison –
myotonic dystrophy type 1 and controls
Compared with controls, in patients with myotonic dystrophy type
1 we detected ubiquitous fractional anisotropy reduction in
association ﬁbres: bilateral superior and inferior longitudinal fas-
cicles, inferior fronto-occipital fascicles and uncinate fascicles, both
fornices, cingulum bundles and hippocampal parts of the posterior
cingulum bundle. The corpus callosum as main commissural tract
was affected in all parts, sparing only parts of the splenium. In
addition, projection ﬁbres as internal capsules (anterior/posterior
limbs, retrolenticular parts) and external capsules, both corticosp-
inal tracts at the level of internal capsules and brainstem at pon-
tine level were affected (Fig. 2, Supplementary Table 3).
The areas of increased radial diffusivity and mean diffusivity
closely mirrored the areas of fractional anisotropy reduction.
Compared with fractional anisotropy reduction, some regions
were even more continuously affected and reached more to the
outlying border of affected ﬁbre tracts. An increase of axial diffu-
sivity was found in parts of regions with fractional anisotropy
reduction (Fig. 3).
Diffusion tensor imaging – group comparison –
myotonic dystrophy type 2 and controls
Compared with controls, in patients with myotonic dystrophy type
2 we detected prominent fractional anisotropy reduction in asso-
ciation ﬁbres: bilateral superior longitudinal fascicles, inferior lon-
gitudinal fascicles, inferior fronto-occipital fascicles, uncinate
fascicles, cingulum bundles and fornices. The corpus callosum
was mainly affected in its anterior parts and more severely af-
fected on the left side. Anterior limbs of both internal capsules
(left 4 right) and both external capsules were affected as projec-
tion ﬁbres (Fig. 2, Supplementary Table 3).
The areas of increased radial diffusivity mirrored those with frac-
tional anisotropy reduction, but there were additional small signiﬁ-
cant areas with increased axial diffusivity in some ﬁbre tracts.
There was little overlap between fractional anisotropy reduction
and increased axial diffusivity in areas of signiﬁcance. An increase
in mean diffusivity was again found in similar regions as fractional
anisotropy reduction, although not all regions with fractional
anisotropy reduction showed an increase of mean diffusivity
(Fig. 3).
Diffusion tensor imaging – group comparison –
myotonic dystrophy types 1 and 2
Direct comparison between both patient groups revealed lower
fractional anisotropy values in patients with myotonic dystrophy
Table 3 Sleep scales in patients with myotonic dystrophy types 1 and 2 compared with controls (mean  SD)
Cut-off
Values
Myotonic
dystrophy
type 1 (n = 22)
Myotonic
dystrophy
type 2 (n = 21)
Controls
(n = 19)
Myotonic
dystrophy
type 1 versus
controls
Myotonic
dystrophy
type 2 versus
controls
Myotonic
dystrophy
type 1 versus
myotonic dystrophy
type 2
F-value (P-value) F-value (P-value) F-value (P-value)
PSQI total-score 45 5.67 (3.43) 5.85 (3.82) 3.11 (2.23) 7.555 (0.009)** 7.287 (0.011)* 0.026 (0.872)
KFSS 43.7 4.38 (1.59) 4.61 (1.73) 2.26 (0.72) 30.387 (0.000)*** 29.742 (0.000)*** 0.118 (0.733)
Daytime Sleepiness Scale 410 11.27 (3.87) 8.76 (5.48) 6.47 (3.06) 17.088 (0.000)*** 2.465 (0.125) 2.601 (0.115)
Epworth Sleepiness Scale 410 9.50 (3.20) 7.19 (4.01) 5.67 (2.35) 16.524 (0.000)*** 1.661 (0.206) 4.005 (0.052)
Ullanlinna 413 9.68 (5.02) 6.10 (3.16) 5.42 (1.92) 11.925 (0.001)** 0.866 (0.358) 7.195 (0.011)*
*P50.05, **P50.01, ***P50.001.
Ullanlinna = Ullanlinna-Narcolepsy Scale.
3532 | Brain 2011: 134; 3527–3543 M. Minnerop et al.type 1 in some parts of bilateral superior longitudinal fascicles and
inferior longitudinal fascicles, right corticospinal tract—which was
not affected in myotonic dystrophy type 2—and in parts of the
corpus callosum. We did not ﬁnd lower fractional anisotropy
values in myotonic dystrophy type 2 when compared with myo-
tonic dystrophy type 1 (Fig. 2).
Diffusion tensor imaging – correlation analyses with
clinical and neuropsychological data – myotonic
dystrophy type 1
Lower fractional anisotropy values occurred with higher age, longer
disease duration, larger CTG repeat expansion sizes, higher Muscular
Impairment Rating Scale score and poorer manual motor perform-
ance in various brain regions, predominantly association ﬁbres,
fornix, cingulum bundles, corpus callosum and left external capsule.
Most notably, regions associated with higher age were identical with
those associated with longer disease duration. In addition, fractional
anisotropy values oftheposterior limb ofthe leftinternal capsule and
left external capsule correlated not only with age and disease dur-
ation, but also with motor performance (and with depressed mood).
Regions in which reduced fractional anisotropy values occurred with
poorer motor performance overlapped only partially with regions in
which reduced fractional anisotropy values correlated with the
Muscular Impairment Rating Scale score (only right superior longitu-
dinal fascicle and inferior longitudinal fascicle). Unexpectedly, frac-
tional anisotropy values were lower in patients with less fatigue
(lower KFSS scores) and less depressed mood (lower BDI scores).
Whereasthecorpuscallosumwasoneofthemostprominentregions
affected in correlation analyses with the BDI score, we saw only
minor callosal body involvement in correlation analyses with the
KFSS score. Instead, there was a prominent involvement of the
dorsal brainstem, not depicted in association with the BDI score.
This region showed further correlations with age/disease duration
(Fig. 4). Further details of fractional anisotropy correlation analyses
with clinical parameters are given in Supplementary Table 4.
In contrast to correlation analyses of fractional anisotropy data
with clinical parameters, correlation analyses with
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Table 5 White matter hyperintensities rated according the
ARWMC scale in patients with myotonic dystrophy types 1
and 2 and control subjects (mean  SD)
Myotonic
dystrophy
type 1
patient group
Myotonic
dystrophy
type 2
patient group
Control
group
Total score 1.82  2.79
(0.03)*
1.0  1.75
(0.15)
0.39  0.66
Frontal subscore 1.18  1.68
(0.00)*
0.55  0.86
(0.02)*
0.09  0.29
Parieto-occipital
subscore
0.45  1.14
(0.52)
0.45  1.10
(0.51)
0.26  0.62
Temporal subscore 0.18  0.85
(0.32)
00
Infratentorial
subscore
0 (0.32) 0 (0.32) 0.04  0.21
*Signiﬁcant differences (P50.05) between patient and control groups. P-values
are given in brackets.
ARWMC = age-related white matter change score.
The brain in myotonic dystrophies Brain 2011: 134; 3527–3543 | 3533Figure 1 Neuroimaging results of the brain (VBM, group comparisons). Displayed results of VBM analyses are based on a threshold of
Pfalse discovery rate50.05 at voxel-level with an extended cluster threshold of 10 voxels. The coordinates refer to the MNI reference space.
(A) Grey matter decrease in patients with myotonic dystrophy type 1 compared with controls. (B) White matter decrease in patients with
myotonic dystrophy type 1 compared with controls. (C) Grey matter decrease in patients with myotonic dystrophy type 2 compared with
controls (no clusters detected). (D) White matter decrease in patients with myotonic dystrophy type 2 compared with controls.
3534 | Brain 2011: 134; 3527–3543 M. Minnerop et al.neuropsychological tests (interference, choice reaction time, verbal
memory test) gave mixed results with marginal and inconsistent
associations that involved only few voxels (data not shown).
Diffusion tensor imaging – correlation analyses with
clinical and neuropsychological data – myotonic
dystrophy type 2
Lower fractional anisotropy values occurred with higher age,
longer disease duration and poorer motor performance in various
brain regions, especially association ﬁbres, cingulum bundles, for-
nices, anterior limb of internal capsules, corpus callosum and right
external capsule. With respect to higher age and longer disease
duration, we found more frontally accentuated reduced fractional
anisotropy values compared with myotonic dystrophy type 1,
affecting comparable but not identical ﬁbre parts. Further, the
changes were more pronounced with age than with disease dur-
ation. Correlation analyses of fractional anisotropy values with
motor performance showed regions in the right external capsule,
while in contrast to myotonic dystrophy type 1 no associations
with posterior limbs of internal capsules were present. In contrast
to myotonic dystrophy type 1, lower fractional anisotropy values
were associated with a more depressed mood and increased
fatigue in myotonic dystrophy type 2 (Fig. 4). Further details of
fractional anisotropy correlation analyses with clinical parameters
are given in Supplementary Table 4.
Correlation analyses with neuropsychological tests (interference,
focused attention) did not show signiﬁcant results (data not
shown).
Discussion
We present a comprehensive study of brain structure and function
in a comparably large series of patients with myotonic dystrophy
types 1 and 2. Our neuroimaging ﬁndings conﬁrmed the major
hypotheses of our study: we found severe white matter effects in
patients with myotonic dystrophy type 1, more than in patients
with myotonic dystrophy type 2, which extensively exceeded grey
matter involvement in both disorders. We applied DTI based on
diffusion MRI, which is a suitable method for white matter evalu-
ation. Even though VBM is not the method of choice for white
Figure 2 Neuroimaging results of the brain (DTI, group comparison of fractional anisotropy values). Displayed results of tract-based
spatial statistics analyses of fractional anisotropy values (group comparison) are based on a corrected threshold of Pfamily wise error50.05.
Mean tract-based spatial statistics tract skeleton is overlaid on the mean fractional anisotropy image (display threshold of 0.1). The
coordinates refer to the MNI reference space. (A) Fractional anisotropy reduction in patients with myotonic dystrophy type 1 compared
with healthy controls. (B) Fractional anisotropy reduction in patients with myotonic dystrophy type 2 compared with healthy controls.
(C) Fractional anisotropy reduction in patients with myotonic dystrophy type 1 compared with patients with myotonic dystrophy type 2.
The brain in myotonic dystrophies Brain 2011: 134; 3527–3543 | 3535matter evaluation, our DTI results were strongly supported by
VBM analyses.
White matter effects were found throughout the whole brain in
myotonic dystrophy types 1 and 2, affecting association ﬁbres,
commissural ﬁbres (mainly corpus callosum), and projection ﬁbres
in the brainstem, internal and external capsules, the latter connect-
ing prefrontal and temporal cortical areas with the striatum.
Thalamocortical pathways (e.g. anterior thalamic radiation) and
prefrontal connections are represented in anterior limbs of internal
capsules, which were affected in myotonic dystrophy types 1 and 2.
Interestingly, anterior limb lesions had previously been described in
the context of behavioural problems and cognitive dysfunction
(Mamah et al., 2010). In contrast, central motor pathways
(e.g. corticospinal tracts located in posterior limbs of internal
capsules) were exclusively affected in myotonic dystrophy type 1.
Our data on white matter in adult patients with myotonic dys-
trophy type 1 give evidence that callosal body affection is not
restricted to congenital myotonic dystrophy type 1. Current results
conﬁrm callosal body affection in patients with myotonic dystro-
phy type 2 as previously demonstrated by our VBM and
surface-based morphometry analyses (Minnerop et al., 2008),
and demonstrate a predominant affection of anterior callosal
ﬁbres connecting frontal lobes in myotonic dystrophy type 2.
We further found degradation of major pathways of the limbic
system (e.g. fornix, cingulum bundle) in patients with myotonic
dystrophy type 1, more than in patients with myotonic dystrophy
type 2. This ﬁnding could be associated with behavioural abnorm-
alities and emotional disturbances in myotonic dystrophies. This
question should be addressed in future studies investigating per-
sonality traits in both disorders.
In the current patient series, cortical grey matter affection was
only found in myotonic dystrophy type 1. Cortical grey matter loss
was located in frontal and parietal regions, whereas subcortical
grey matter loss was detected in thalamic and basal ganglia struc-
tures. This is in line with the literature, describing widespread cor-
tical and subcortical grey matter alterations in myotonic dystrophy
type 1 (Antonini et al., 2004; Weber et al., 2010). Previous ana-
lyses, including one of our own studies, also found grey matter
changes in myotonic dystrophy type 2 (Minnerop et al., 2008;
Weber et al., 2010). This discrepancy to our present data may
be attributed to differences in sample size as earlier studies inves-
tigated smaller patient cohorts.
Figure 3 Neuroimaging results of the brain (DTI, group comparison of fractional anisotropy values, axial, radial and mean diffusivity).
Displayed results of tract-based spatial statistics analyses of different diffusivity indices (fractional anisotropy, axial diffusivity, radial
diffusivity, mean diffusivity) are based on a corrected threshold of Pfamily wise error50.05. Mean tract-based spatial statistics tract skeleton
is overlaid on the mean fractional anisotropy image (display threshold of 0.1). The coordinates refer to the MNI reference space. (A and E)
Fractional anisotropy reduction in patients with myotonic dystrophy type 1 (A) and patients with myotonic dystrophy type 2 (E) compared
with healthy controls. (B and F) Increase in axial diffusivity in patients with myotonic dystrophy type 1 (B) and patients with myotonic
dystrophy type 2 (F) compared with healthy controls. (C and G) Increase in radial diffusivity in patients with myotonic dystrophy type 1
(C) and patients with myotonic dystrophy type 2 (G) compared with healthy controls. (D and H) Increase of mean diffusivity in patients
with myotonic dystrophy type 1 (D) and patients with myotonic dystrophy type 2 (H) compared with healthy controls.
3536 | Brain 2011: 134; 3527–3543 M. Minnerop et al.Figure 4 Neuroimaging results of the brain (DTI, correlation analyses between white matter affection (fractional anisotropy values) and
clinical parameters). Correlation analyses in myotonic dystrophy type 1 (A–G) and myotonic dystrophy type 2 (H–L). Displayed results of
Tract-based spatial statistics analyses of fractional anisotropy values are based on a corrected threshold of Pthreshold-free cluster enhance-
ment50.05. Mean tract-based spatial statistics tract skeleton is overlaid on the mean fractional anisotropy image (display threshold of 0.1).
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(continued)Though our patients with myotonic dystrophy type 2 were older
than our patients with myotonic dystrophy type 1, the myotonic
dystrophy type 2 cohort encompassed rather ‘young’ subjects
regarding the common disease manifestation at higher ages.
With respect to the clinical course of myotonic dystrophy type
2, an older cohort with longer disease durations might have
been more appropriate. Less pronounced cerebral grey and
white matter affection in patients with myotonic dystrophy type
2 compared with patients with myotonic dystrophy type 1 might
be partially explained by this fact.
White matter lesions and brain atrophy are well known in myo-
tonic dystrophy types 1 and 2, but current data stress that the
underlying pathology seems to (i) affect white matter much more
than grey matter and (ii) affect white matter far beyond circum-
scribed white matter lesions visible on T2-weighted MRIs. These
ﬁndings link myotonic dystrophies to the growing group of brain
disconnection disorders. The neuropathological background of
white matter changes in myotonic dystrophies is still not fully
understood. Neuropathological ﬁndings in myotonic dystrophy
type 1 brains include abnormalities like intracytoplasmic inclusions
in thalamus, striatum, cerebral cortex and brainstem (Rosman and
Kakulas, 1966; Wis ´niewski et al., 1975; Ono et al., 1987). Further
studies in myotonic dystrophy type 1 and myotonic dystrophy
type 2 brains found evidence of neuroﬁbrillary degeneration
with intracellular aggregation of microtubule-associated tau pro-
tein (Vermersch et al., 1996; Sergeant et al., 2001; Maurage
et al., 2005; Itoh et al., 2010). Most changes are located in
neurons; however, white matter alterations including disordered
arrangement of myelin sheaths and axons have been described
(Abe et al., 1994; Ogata et al., 1998; Itoh et al., 2010). It is
widely accepted that the integrity of axonal membranes and
myelin sheaths are the main biological causes of anisotropy in
DTI (Beaulieu, 2002). Reduced fractional anisotropy values in the
current study were primarily linked with an increase of radial
diffusivity. Increased radial diffusivity can be either caused by
reduced myelin sheaths/defect axonal membranes or as a conse-
quence of neuronal cell loss with Wallerian degeneration. A likely
explanation for our ﬁnding of an additional increase of axial dif-
fusivity (theoretically leading to an increase of fractional anisot-
ropy) in some areas with fractional anisotropy reduction is
increased water content in the context of atrophy as described
in the ‘healthy’ ageing brain (Moseley, 2002). This phenomenon
leads to an increase of both radial more than axial diffusivity,
ﬁnally resulting in a decrease of fractional anisotropy. The changes
of diffusivity in white matter ﬁbre tracts were more prominent in
myotonic dystrophy type 1 than type 2. This is possibly a con-
sequence of genetic differences with a disease-speciﬁc pathome-
chanism of tissue destruction, which however results in abnormal
increases of water diffusion perpendicular to axons in both
disorders. We have to consider that reduced fractional anisotropy
values in genetically determined disorders might not reﬂect on-
going destructive processes, but instead a developmental defect
with disturbed assembly of myelin and/or axonal membranes. The
widespread changes in myotonic dystrophy type 1 may point to-
wards a generalized white matter defect. However, the correlation
of lower fractional anisotropy values with longer disease duration
and higher age in myotonic dystrophy type 1 and myotonic dys-
trophy type 2 strongly argue for an ongoing destruction of myelin
and/or axonal loss over time. The fact that white matter changes
by far dominated the extent of grey matter changes in myotonic
dystrophy types 1 and 2 might further argue against Wallerian
degeneration as the major cause of white matter alterations as
formerly postulated (Ota et al., 2006).
Relation of white matter integrity and
motor function
Impaired motor function due to muscle affection is one of the
most characteristic symptoms in myotonic dystrophy types 1 and
2. However, subclinical dysfunction of the central motor system
had been described in myotonic dystrophy type 1 (Oliveri et al.,
1997; Mitsuoka et al., 2003). We found reduced fractional anisot-
ropy values in posterior limbs of internal capsules (corticospinal
tract) in myotonic dystrophy type 1, not in myotonic dystrophy
type 2, which correlated with motor performance in a simple
motor task (bimanual pegboard). In the group comparison, we
found reduced fractional anisotropy values along external capsules
in patients with myotonic dystrophy types 1 and 2, correlating
with the Muscular Impairment Rating Scale score (measuring mus-
cular impairment) in myotonic dystrophy type 1 and motor per-
formance in myotonic dystrophy type 1 and type 2. The external
capsule contains corticostriatal projection ﬁbres connecting (pre)-
frontal and temporal areas with basal ganglia, known to play a
major role in motion planning and execution. A recent functional
MRI study in myotonic dystrophy type 1 showed activation pat-
terns in central motor system areas that resembled those in
healthy older subjects (Caramia et al., 2010). Taken together,
these ﬁndings give evidence of impaired central motor functioning
in myotonic dystrophies, potentially reﬂecting an accelerated or
increased ageing process.
Neuropsychological performance
Neuropsychological deﬁcits, especially of executive and visuo-
spatial functions, have been frequently described in myotonic dys-
trophy types 1 and 2 (Meola et al., 1999, 2003; Gaul et al., 2006;
Meola and Sansone, 2007; Romeo et al., 2010). However, most
Figure 4 Continued
The coordinates refer to the MNI reference space. Correlations of fractional anisotropy values in patients with myotonic dystrophy type 1
with age and disease duration (A and B), CTG repeat length (C), Muscular Impairment Rating Scale score (D), motor performance (E).
Positive correlation of fractional anisotropy values in patients with myotonic dystrophy type 1 with depressed mood (BDI score, F) and
fatigue (KFSS score, G). Correlations of fractional anisotropy values in patients with myotonic dystrophy type 2 with age (H), disease
duration (I) and motor performance (J). Negative correlations of fractional anisotropy values in patients with myotonic dystrophy type 2
with depressed mood (BDI score, K) and fatigue (KFSS score, L).
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response, which may be impaired in myotonic dystrophies.
While several neuropsychological studies did not address impaired
motor performance as a possible confounding factor in their study
design, other studies tried to solve this issue by excluding patients
with a certain degree of muscular impairment (Meola et al., 2003;
Gaul et al., 2006) or to select motor-independent tests (Modoni
et al., 2004; Gaul et al., 2006). We tried to correct for motor
performance by including a score for ﬁne motor skills as covariate.
We found only minor neuropsychological deﬁcits in our patients.
Patients with myotonic dystrophy type 1, usually thought to be
more cognitively impaired than patients with myotonic dystrophy
type 2, even showed a better performance in the verbal memory
task compared with controls. This is not explained by age differ-
ences of patients with myotonic dystrophy type 1 and controls,
since patients with myotonic dystrophy type 1 still performed
above average in comparison to age-matched normative data.
Increased liability for interference was the only signiﬁcant neuro-
psychological deﬁcit in our myotonic dystrophy type 1 series and
also signiﬁcantly present in myotonic dystrophy type 2, which
additionally showed impaired focused attention, pointing towards
frontal lobe dysfunction in both myotonic dystrophy types 1 and
2. These results are in line with earlier studies showing that
impaired frontal lobe function is a predominant ﬁnding in myo-
tonic dystrophies (Meola et al., 2003). The discrepancy regarding
the extent of cognitive deﬁcits between previous studies and our
results might be at least partially explained by methodological
differences as correction for ﬁne motor performance. This is sup-
ported by ﬁndings of Gaul et al. (2006) who also found only
subtle prefrontal lobe dysfunction when excluding patients with
severe motor impairment and selecting more motor-independent
tests. The clinical impression of cognitive decline particularly in
adult patients with myotonic dystrophy type 1 may thus be
partly unjustiﬁed and rather due to a combination of facial
muscular weakness, depression and the highly underestimated,
however frequent and treatable, symptoms of fatigue/increased
daytime sleepiness. One further explanation for the presence of
only minor neuropsychological deﬁcits in our patient series might
be a selection bias towards cognitively less severely affected
individuals. The study participation lasted about 4–5h in an
outpatient setting, and patients with a serious mental impairment
might have been more likely to refuse study participation.
Third, there is some evidence that neuropsychological deﬁcits in
myotonic dystrophies might partially escape commonly applied
neuropsychological test batteries due to still unclear reasons. This
observation is primarily based on the personal experience of
neurologists and neuropsychologists specialized in myotonic dys-
trophies. Consequently, a current international intention is to ﬁnd
a consensus on neuropsychological tests to be generally recom-
mended for use in patients with myotonic dystrophy worldwide.
Accordingly, the most sensitive and reliable, best validated, and
most applicable tests are expected to be selected in the near
future. Our neuropsychological test selection was a compromise
resulting from our experience in patients with neurological/neuro-
degenerative disorders and the time constraints that were dictated
by the study protocol (combined neuroimaging study). For prac-
tical reasons, we used (i) the German NeuroCogFX, which is
validated in a variety of neurological disorders and has also been
applied to other trinucleotide repeat disorders (Fliessbach et al.,
2006; Hoppe et al., 2009; Klinke et al., 2010) and (ii) the
Cerebraler Insufﬁzienztest (Lehrl and Fischer, 1997), which
assesses attention and interference in a reliable and fast way com-
pared with other frontal lobe function tests. However, some of the
applied tests had not previously been systematically used in myo-
tonic dystrophies. Thus, the selection of the neuropsychological
test battery might have additionally inﬂuenced the neuropsycho-
logical proﬁling of our patients.
Relation of white matter integrity and
depression
Depressive symptoms are well known in myotonic dystrophy types
1 and 2, but do not seem to be a prominent feature if DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders) criteria are
applied (Meola and Sansone, 2007). Using the self-rating ques-
tionnaire BDI, Winblad et al. (2010) found signs of mostly mild
depression in 32% of examined patients with myotonic dystrophy
type 1, which is identical to our ﬁndings in myotonic dystrophy
type 1 (32%) and type 2 (38%). However, it is still a matter of
debate if depression might be a consequence of structural brain
damage or rather a reactive adjustment disorder. We therefore
investigated the interaction between fractional anisotropy reduc-
tion and BDI scores and found higher BDI scores associated with
higher fractional anisotropy values in myotonic dystrophy type 1,
whereas higher BDI scores were associated with lower fractional
anisotropy values in myotonic dystrophy type 2. Regression ana-
lyses in myotonic dystrophy type 1 and type 2 revealed a decline
of fractional anisotropy with increasing age and disease duration.
Thus, our results implicate that depressed mood in myotonic dys-
trophy type 1 might be more pronounced in earlier disease stages,
whereas depression is more likely to be found in later disease
stages of myotonic dystrophy type 2. Our results are supported
by recent data of Winblad et al. (2010): the authors found less
depressive symptoms in patients with myotonic dystrophy type 1
with a longer disease duration and presence of white matter
lesions, whereas patients with myotonic dystrophy type 1 without
white matter lesions had more depressive symptoms (Winblad
et al., 2010). If depressed mood was a consequence of structural
brain affection, a continuous worsening of depression would
be expected as myotonic dystrophy types 1 and 2 progress. Our
results indicate that depression might be a reactive adjustment
disorder rather than a consequence of structural brain damage in
myotonic dystrophies. Myotonic dystrophy type 1 is more severe
in general and leads to a more serious impairment in earlier life
than myotonic dystrophy type 2. Therefore, patients with myoton-
ic dystrophy type 1 are more likely to notice early limitations in
everyday activities and develop reactive depression. As disease
progresses, these patients may develop efﬁcient coping strategies
or may be less able to perceive their limitations due to cognitive
deﬁcits or personality changes. Since we found only minor neuro-
psychological deﬁcits, the so called ‘lack of awareness’ may
explain the presence of a less depressed mood in advanced disease
stages (Meola and Sansone, 2007; Winblad et al., 2010). This
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other disorders, affecting regions (prefrontal cortex, frontal and
parietotemporal areas, thalamus) that also show structural
abnormalities in myotonic dystrophy type 1 (Orfei et al., 2008;
Winblad et al., 2010). Myotonic dystrophy type 2 is usually less
severe, and patients may not notice serious limitations in everyday
life in early disease stages. Symptoms worsen over time and may
cause depression in advanced disease stages. However, we did not
ﬁnd direct correlations between BDI scores and age or disease
duration in myotonic dystrophy type 1 or 2.
The use of additional depression scores would have been
favourable, though was not practicable in the present comprehen-
sive study setting, which took several hours and required careful
consideration of patients’ psychophysical limits as well as time
constraints.
Relation of white matter integrity and
increased daytime sleepiness/fatigue
Increased daytime sleepiness and fatigue are among the most fre-
quent non-muscular symptoms in patients with myotonic dystro-
phy type 1 and type 2 (Hilton-Jones, 1997; van der Werf et al.,
2003; Meola and Sansone, 2007; Laberge et al., 2009a, b;
Tieleman et al., 2010). Weak oropharyngeal and respiratory
muscles leading to obstructive sleep apnoea and alveolar hypoven-
tilation have been regarded as causative factors of daytime sleepi-
ness. However, there is increasing evidence that tiredness primarily
results from CNS dysfunction rather than progressive respiratory
weakness (van der Meche ´ et al., 1994; Park and Radtke, 1995;
Rubinsztein et al., 1998; Laberge et al., 2009a, b; Romigi et al.,
2011; Yu et al., 2011). An association with the hypocretin neuro-
transmission system had been suggested. However, data regarding
the role of hypocretin-1, a hypothalamic neuropeptide essential in
the regulation of the sleep/wakefulness cycle and vigilance, are
still controversial (Martı ´nez-Rodriguez et al., 2003; Ciafaloni et al.,
2008).
Fatigue, equivocally deﬁned as a lack of energy and feeling of
exhaustion (Shen et al., 2006), is a prominent and common com-
plaint in myotonic dystrophy type 1 (60–80%; Kalkman et al.,
2005; Meola and Sansone, 2007; Laberge et al., 2009b;
Tieleman et al., 2010). The prevalence of fatigue in myotonic
dystrophy type 2 has been investigated only very recently, ﬁnding
a similar result of 66% (Tieleman et al., 2010). These data are in
accordance with our ﬁndings, showing a prevalence of 68–70%
fatigue in patients with myotonic dystrophy types 1 and 2. While
our patients with myotonic dystrophy type 1 differed from con-
trols in all sleepiness and fatigue scales, patients with myotonic
dystrophy type 2 differed from controls only in PSQI and KFSS
scores, not in daytime sleepiness scales. This again is in line with
ﬁndings of Tieleman et al. (2010). Subjective sleep quality, as
measured by the total PSQI score, was impaired in 40% of
both patient groups, which might be an indicator of a disturbed
sleep/awakening cycle in myotonic dystrophy types 1 and 2 and
should be further examined by polysomnographic studies.
We performed correlation analyses to evaluate the relation be-
tween fatigue (KFSS score) and white matter integrity (fractional
anisotropy values). Similar to results of regression analyses with
BDI scores, we found that higher fractional anisotropy values
were associated with more pronounced fatigue in myotonic dys-
trophy type 1. In contrast, lower fractional anisotropy values were
associated with more pronounced fatigue in myotonic dystrophy
type 2. In contrast to previous ﬁndings, anterior corpus callosum
integrity did not correlate with fatigue in our study (Giubilei et al.,
1999).
Damage to the reticular activating system of the upper brain-
stem and/or to its cortical projections has already been discussed
as related to the chronic fatigue syndrome (Dickinson, 1997).
Morphological brainstem changes in myotonic dystrophy type 1
include neuroﬁbrillary tangles, Marinesco bodies, as well as a
decrease of serotonergic neurons in raphe nuclei and catecholami-
nergic neurons in the medullary reticular formation (Ono et al.,
1987, 1998a, b; Oyamada et al., 2006). Interestingly, sleep
disturbances and apathy were more frequent in patients with
myotonic dystrophy type 1 with fewer neuroﬁbrillary tangles
(Oyamada et al., 2006). We comparably depicted less fatigue
with more pronounced brainstem affection in patients with myo-
tonic dystrophy type 1. Thus, myotonic dystrophy type 1 speciﬁc
brainstem changes might prevent the feeling of fatigue or again
might result in a lack of self-awareness.
Laberge et al. (2009b) found higher depression scores, more
muscular impairment, and higher number of CTG repeats in pa-
tients with myotonic dystrophy type 1 with fatigue and/or
increased sleepiness. This in accordance with our results in myo-
tonic dystrophy type 1, as we found higher KFSS scores correlating
with both poorer motor performance and higher BDI scores.
In contrast, we did not ﬁnd a correlation of KFSS with BDI
scores in myotonic dystrophy type 2, whereas higher KFSS
scores correlated with poorer motor performance similar to myo-
tonic dystrophy type 1 and to controls.
Thus, depressed mood and fatigue were closely related at least
in myotonic dystrophy type 1. BDI and KFSS may overlap with
regard to the target symptoms, and some questions of the BDI are
known to target on symptoms of sleepiness and fatigue. In myo-
tonic dystrophy type 2, we found similar directed correlations of
fractional anisotropy values, BDI and KFSS scores. However, we
did not ﬁnd BDI and KFSS scores correlating with each other as
shown in myotonic dystrophy type 1. Thus, one might conclude
that the applied questionnaires are measuring partially overlap-
ping, but not entirely identical conditions.
Polysomnographic studies as well as the use of further fatigue,
anxiety and apathy scales like the Checklist Individual Strength or
the Hospital Anxiety and Depression Scale would have been of
interest but were not applicable in the current study setting.
However, the present data warrant further investigations in the
near future.
Relation of white matter integrity
and age, disease duration and
CTG repeat size
The pattern of affected ﬁbre tracts in correlation analyses with age
and disease duration was identical in our myotonic dystrophy type
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general is earlier in myotonic dystrophy type 1, usually resulting in
a parallel progression of disease and ageing. Consequently, the
effect of age and disease duration cannot be easily separated in
myotonic dystrophy type 1. However, since age and disease dur-
ation were not correlated in our patient groups, it is tempting to
speculate that the effect of the disease itself on white matter
structure resembles effects of ageing in myotonic dystrophy type
1. In myotonic dystrophy type 2, we found more frontally located
areas with fractional anisotropy reduction that correlated with age
but not with disease duration. This might be interpreted as a
stronger effect of age in these distinct regions. Accelerated or
premature ageing has been discussed in myotonic dystrophy
type 1 (Toscano et al., 2005; Oyamada et al., 2006; Romigi
et al., 2011), and age-speciﬁc translational dysfunctions have
been described in myotonic dystrophy type 2 (Jin et al., 2009).
Frontal-lobe accentuated white matter changes in myotonic dys-
trophy type 2, which correlated with age, may support this hy-
pothesis since fractional anisotropy reduction in frontal regions had
been described in normal ageing previously (Damoiseaux et al.,
2009). A recent study investigated the time course of radial and
axial diffusivity changes during ageing in the callosal body, which
strikingly mirrors diffusivity changes present in our myotonic dys-
trophy type 1 and type 2 groups (Fig. 3; Lebel et al., 2010). The
same study showed a sharp drop of fractional anisotropy values in
anterior regions of the corpus callosum and a more substantial
fractional anisotropy drop in outer sections of the callosal body
with increasing age. While fractional anisotropy values were
reduced along the entire corpus callosum in our myotonic dystro-
phy type 1 series, mainly anterior parts of the callosal body were
affected in myotonic dystrophy type 2. These anterior callosal
body fractional anisotropy reductions correlated with age and
showed the peak fractional anisotropy loss with age in right
outer sections. This might further underline similarities with
normal ageing and might suggest an accelerated or more pro-
nounced ageing process in patients with myotonic dystrophy
types 2 and 1 compared with controls.
CTG repeat expansion sizes in blood are traditionally used as
‘biomarkers’ for disease severity in myotonic dystrophy type 1.
Thus, there are a multitude of neuroimaging studies that have
examined the relation of brain affection and CTG repeat lengths.
However, results are highly controversial, and most studies failed
to ﬁnd any correlations (Kassubek et al., 2003; Antonini et al.,
2004; Di Costanzo et al., 2008). This might be due to the marked
somatic mosaicism of CTG repeat lengths. There are considerable
tissue variations in repeat sizes with rather small expansions in
blood and much larger expansions in heart or skeletal muscle
tissue. Moreover, repeat sizes may increase throughout life even
in post-mitotic tissues, which suggests that repeat lengths in blood
might not correlate with repeat lengths in brain and cerebral af-
fection. Nevertheless, a variety of neuroimaging studies did show
more serious morphological cerebral changes with larger repeat
expansions in adult patients (Ota et al., 2006; Romeo et al.,
2010). Our present ﬁndings equally showed that larger CTG
repeat sizes were associated with more severe white matter affec-
tion in several brain regions. Remarkably, the pattern of ﬁbre tract
degradation that was associated with larger CTG repeats was
similar to the pattern that was associated with higher age and
longer disease duration. These ﬁndings again may indicate that
the effect of the disease itself on white matter structure resembles
the effects of ageing in myotonic dystrophy type 1. Speciﬁc brain
regions might be particularly susceptible to the disease effects that
are reﬂected by CTG repeat lengths and disease duration.
Altogether, our data suggest that white matter affection is pro-
gressive over time in myotonic dystrophies. Despite this tempting
speculation, cross-sectional data and correlation analyses, as
obtained in our study, do not sufﬁciently allow analyses of the
age- and disease duration-related impact on brain morphology
in myotonic dystrophy types 1 and 2. Longitudinal MRI studies
investigating the progress of grey and white matter changes over
time and its role in clinical deterioration in both types of myotonic
dystrophies are strongly required to address these issues appropri-
ately in the future.
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